Molecular Therapy

雜志介紹

Molecular Therapy雜志介紹

《Molecular Therapy》是一本以English為主的未開放獲取國際優秀期刊，中文名稱分子療法，本刊主要出版、報道醫學-BIOTECHNOLOGY & APPLIED MICROBIOLOGY領域的研究動態以及在該領域取得的各方面的經驗和科研成果，介紹該領域有關本專業的最新進展，探討行業發展的思路和方法，以促進學術信息交流，提高行業發展。該刊已被國際權威數據庫SCIE收錄，為該領域相關學科的發展起到了良好的推動作用，也得到了本專業人員的廣泛認可。該刊最新影響因子為12.1，最新CiteScore 指數為19.2。

本刊近期中國學者發表的論文主要有：

• Targeting inflammatory macrophages rebuilds therapeutic efficacy of DOT1L inhibition in hepatocellular carcinoma

  Author: Yang, Yi-Bin; Wu, Cai-Yuan; Wang, Xu-Yan; Deng, Jia; Cao, Wen-Jie; Tang, Yun-Zhi; Wan, Chao-Chao; Chen, Zhi-Tian; Zhan, Wan-Yu; Shan, Hong; Kuang, Dong-Ming; Wei, Yuan

• NLRC3 expression in macrophage impairs glycolysis and host immune defense by modulating the NF-KB-NFAT5 complex during septic immunosuppression

  Author: Xu, Jiqian; Gao, Chenggang; He, Yajun; Fang, Xiangzhi; Sun, Deyi; Peng, Zhekang; Xiao, Hairong; Sun, Miaomiao; Zhang, Pei; Zhou, Ting; Yang, Xiaobo; Yu, Yuan; Li, Ruiting; Zou, Xiaojing; Shu, Huaqing; Qiu, Yang; Zhou, Xi; Yuan, Shiying; Yao, Shanglong; Shang, You

• MAP7D2 reduces CD8+cytotoxic T lymphocyte infiltration through MYH9-HMGB1 axis in colorectal cancer

  Author: Wu, Qian; Yue, Xiao; Liu, Huashan; Zhu, Yaxi; Ke, Haoxian; Yang, Xin; Yin, Shi; Li, Zhihao; Zhang, Yunfeng; Hu, Tuo; Lan, Ping; Wu, Xianrui

• CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma

  Author: Wang, Guoqing; Zhang, Zongliang; Zhong, Kunhong; Wang, Zeng; Yang, Nian; Tang, Xin; Li, Hexian; Lu, Qizhong; Wu, Zhiguo; Yuan, Boyang; Zheng, Meijun; Cheng, Ping; Tong, Aiping; Zhou, Liangxue

英文介紹

Molecular Therapy雜志英文介紹

Molecular Therapy is the leading international journal for research on the development of molecular and cellular therapeutics to correct genetic and acquired diseases, including but not limited to research on gene transfer and editing, vector development and design, stem cell manipulation, vaccine development, pre-clinical target validation, safety/efficacy studies, and clinical trials.